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Abstract
After a successful heart transplantation, fundamental keys to achieve good results in the 
long term are to establish immunosuppressive therapy in the postoperative period in an 
appropriate manner and to ensure continuity of follow-ups. Despite the fact that these 
stages are maintained perfectly, patients may face one or more rejection episodes. T-cell-
mediated acute cellular rejection of the cardiac allograft has well-established treatment 
algorithms, whereas antibody-mediated rejection (AMR) is challenging to diagnose, and 
its treatment varies between centers. Investigators reported that AMR is among the most 
important factors to improving long-term outcomes. Improved understanding of the 
roles of acute and chronic AMR has evolved in recent years following a major progress in 
the technical ability to detect and quantify recipient antihuman leukocyte antigen (HLA) 
antibody production. Recently, a study of the immunobiology of B cells and plasma cells 
that pertains to allograft rejection and tolerance has emerged. There are some questions 
regarding the classification of AMR, the diagnostic approaches, and the treatment strate-
gies for managing. In this chapter, we are discuss the effector mechanisms that are used 
by antibodies to eliminate antigens and clinical experience about AMR and its treatment 
with a discussion about the latest articles.
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1. Introduction
Orthotopic heart transplantation (OHT) is still the gold standard of treatment among end-
stage heart failure. Worldwide, about 3500 heart transplantations are performed annually [1]. 
However, shortage of donors and allograft dysfunction are the most common problems cardiac 
surgeons have to cope with. Rejection is the most common reason for allograft dysfunction and 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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is responsible for 25% of postoperative deaths [2]. Episodes of rejection may emerge at any time 
after transplantation as acute or chronic cellular rejection (CR), humoral rejection (=antibody-
mediated = vascular rejection (AMR)), or mixed rejection. Despite AMR that is known to be 
rare, it is potentially lethal due to the capillary vasculopathy caused by neutrophil and macro-
phage infiltration in endothelial cells [3, 4]. Today, treatment of rejection episodes is directed 
mostly to cellular response. Each center sets the treatment in the light of their experience. In this 
chapter, we will discuss the effector mechanisms that are used by antibodies to eliminate anti-
gens and clinical experience about AMR and its treatment with discussing the latest articles.
2. Overview of humoral immunity
Antibodies are accumulated by the immune system to identify and neutralize foreign objects. 
They were the first specific product of the adaptive immune response to be identified and are 
found in the plasma, in the blood, and in extracellular fluids. Immunity mediated by antibod-
ies is known as humoral immunity because of body fluids that were once known as humors 
[4]. The humoral immune response begins with the recognition of antigens by native B cells. 
These cells then undergo a process of clonal expansion and differentiation. In this way, the B 
cell matures into antibody-secreting plasma cells, which secrete antibodies. The activation of 
B cells and their differentiation into antibody-secreting plasma cells is triggered by antigen 
and usually requires helper T cells. The term “helper T cell” is often used to mean a cell from 
the TH2 class of CD4 T cells, but a subset of TH1 cells can also help in B-cell activation [5]. B 
cells can receive help from helper T cells when antigen bound by surface immunoglobulin is 
internalized and returned to the cell surface as peptides bound to major histocompatibility 
complex (MHC) class II molecules. MHC then delivers activating signals to the B cell. Thus, 
protein antigens binding to B cells both provide a specific signal to the B cell by cross-linking 
its antigen receptors and allow the B cell to attract antigen-specific T-cell help. These antigens 
are unable to induce antibody responses in animals or humans who lack T cells, and they 
are therefore known as thymus-dependent antigens [5]. The first signal required for B-cell 
activation is delivered through its antigen receptor. For thymus-dependent antigens, the sec-
ond signal is delivered by a helper T cell that recognizes degraded fragments of the antigen 
as peptides bound to MHC class II molecules on the B-cell surface; the interaction between 
CD40 ligand on the T cell and CD40 on the B cell contributes an essential part of this sec-
ond signal [5]. For thymus-independent antigens, the second signal can be delivered by the 
antigen itself or by non-thymus-derived accessory cells. The B-cell co-receptor complex of 
CD19:CD21:CD81 can greatly enhance B-cell responsiveness to antigen. CD21 (=complement 
receptor 2) is a receptor for the complement fragment C3d. Whether binding of CD21 enhances 
B-cell responsiveness by increasing B-cell signaling, by inducing co-stimulatory molecules on 
the B cell, or by increasing the receptor-mediated uptake of antigen is not yet known [5]. 
Antibodies are the effector products of humoral immunity. Finally, as this response declines, 
a pool of memory cells remains behind. If the body is reexposed to the antigen, these memory 
cells will recognize the antigen and respond much more quickly and effectively [6]. There are 
two purposes of antibodies. The first purpose is to neutralize the target threat, and the second 
purpose is to recruit other cells or proteins to an antigen so that those cells or proteins can 
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eliminate the antigen [6]. AMR develops when recipient antibody is directed against donor 
human leukocyte antigens (HLA) on the endothelial layer of the allograft. Antibodies induce 
fixation and activation of the complement cascade, resulting in tissue injury. Complement 
and immunoglobulin are deposited within the allograft microvasculature, which results in 
an inflammatory process that is characterized by endothelial cell activation, upregulation of 
cytokines, infiltration of macrophages, increased vascular permeability, and microvascular 
thrombosis. This process ultimately manifests as allograft dysfunction [6].
3. Humoral rejection (=antibody-mediated = vascular rejection 
(AMR))
AMR is mediated by donor-specific antibodies and is histologically defined by linear deposits 
of immunoglobulin (Ig) and complement in the myocardial capillaries [7]. Herskowitz et al. 
[8] described AMR for the first time in 1987 as an arteriolar vasculitis with poor outcome. 
Hammond et al. [9] firstly demonstrated that vascular rejection is associated with deposits 
of antibodies and complement activation. AMR incidence is reported between 8 and 15% 
[10–12], and it has been reported concurrent with CR in up to 24% of cases. Approximately 
50% of heart transplant recipients who develop rejection >7 years after transplantation have 
evidence of AMR [12]. AMR was described as an acute phenomenon seen in weeks to months 
just after OHT. However, in recent years, studies have been reported that it also occurs in 
the longer term [9, 13, 14]. Rejection can be hyperacute (occurring within minutes after the 
vascular anastomosis (0–7 days)) in patients who are sensitized to donor HLA antigens and 
acute (occurring days to weeks after transplantation) because of the development of de novo 
donor-specific antibody (DSA) and preexisting DSA. Early AMR tends to be associated with 
a higher prevalence of allograft dysfunction and hemodynamic compromise. Late (occurring 
3 months after transplantation) or chronic rejection most likely because of heightened recog-
nition (occurring months to years after transplantation) [15]. Risk factors include young age, 
female gender, high levels of pretransplant panel-reactive antibodies (PRAs), positive donor-
specific crossmatch, cytomegalovirus infection, prior OKT3 use, and artificial heart devices 
[10, 13]. Olsen et al. [16] stated that 23% of patients had AMR episodes for the second time 
resulting in graft loss in two-thirds due to the continuous complement activation and produc-
tion of donor-reactive antibodies that cause graft dysfunction by sensitized memory B cells. 
As the definition of AMR has evolved and more sensitive diagnostic modalities have become 
available, there is increasing evidence that AMR is a spectrum of immunologic injury that 
ranges from subclinical, histological, immunologic, and/or serological findings without graft 
dysfunction (i.e., subclinical AMR) to overt AMR with hemodynamic compromise.
3.1. Diagnosis
The first description of humoral rejection was included in the 1990 International Society of 
Heart and Lung Transplantation (ISHLT) criteria defined as positive immunofluorescence, 
vasculitis, or severe edema in the absence of cellular infiltrate [14, 17]. The classification AMR 
0 was assigned in the absence of histological or immunopathologic features. Confirmation of 
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AMR or AMR 1 was defined as histological evidence with identification of antibodies (CD68, 
CD31, C4d) and serum presence of DSA [14]. ISHLT Immunopathology Task Force provided 
an expanded description of the histological evidence of acute capillary injury, the minimum 
requirement for immunopathologic evidence of antibody-mediated injury, and an improved 
definition of serological evidence of circulating antibodies in 2006 [18]. The persistent varia-
tions in the diagnosis and treatment of AMR were addressed in the Heart Session of the Tenth 
Banff Conference on Allograft Pathology (2009) and the ISHLT Consensus Conference on 
AMR (2010) conferences. The most important issues included the need for a clinical definition 
of AMR, the significance of asymptomatic patient without cardiac dysfunction biopsy-proven 
AMR, and the recognition that AMR may be caused by DSA as well as antibodies to non-HLA 
antigens. Although AMR would be a pathological diagnosis, it was strongly recommended 
that at the time of suspected AMR, blood can be drawn at biopsy and tested for the presence 
of donor-specific anti-HLA class I and class II antibodies [14]. On the basis of the initial Banff 
criteria, a definitive diagnosis of AMR required morphologic evidence (primarily microvas-
cular inflammation), immunohistological (C4d staining), and serologic criteria (presence of 
circulating DSA). These criteria were modified to address the current evidence of the existence 
of C4d-negative AMR and lesions of intimal arteritis secondary to the action of the antibod-
ies at the Banff Consensus in 2013 [19]. The myocardial capillaries, arterioles, and venules 
are readily sampled at biopsy. The vascular endothelium is the point of the first contact for 
anti-donor antibody in the allograft and the primary locus of activity in AMR. The appearance 
of vasculitis or leukocytes infiltrating through the endothelium into the vessel wall demon-
strates active humoral immunity with antibody-dependent cytotoxicity, cytokine, and circu-
lating monocyte recruitment [20, 21]. Mechanisms of immune complex-mediated neutrophil 
recruitment and tissue injury. Antibodies induce fixation and activation of the complement 
cascade, resulting in tissue injury. Complement activation, a key contributor to the pathogen-
esis of AMR, results in activation of the innate and adaptive immune responses. Complement 
and immunoglobulin are deposited within the allograft microvasculature, which results in an 
inflammatory process that is characterized by endothelial cell activation, upregulation of cyto-
kines, infiltration of macrophages, increased vascular permeability, and microvascular throm-
bosis. Interstitial edema and hemorrhage are also seen. Capillary changes indicative of AMR 
include endothelial cell swelling and intravascular macrophage accumulation coincident with 
pericapillary neutrophils. The role of immunoglobulins, complement activation, and coagula-
tion cascade in AMR is under constant study as diagnostic methods increase in sensitivity and 
specificity [14, 22]. It has been suggested that AMR is a clinical pathological continuum that 
begins with a latent humoral response of circulating antibodies and then progresses through 
a silent phase of circulating antibodies with C4d deposition without clinical or histological 
alterations, to a subclinical stage, to symptomatic AMR [14]. Mauiyyedi et al. described the 
correlation between DSAs and diffuse C4d deposition (>50%) as diagnostic markers for AMR 
[23]. C4d deposition may be earlier than 3 months, as may be after 160 months [7, 10, 24]. The 
complement components C3 and C1q have been demonstrated in kidney AMR; however, their 
detection is limited by a short half-life in vivo and consequently a short window of detection 
during a rejection episode [25]. The protein C4d is a complement split product that binds 
covalently to the endothelium at the site of complement activation and persists longer than C3 
or C1q [14]. C4d and C3d detection predicts graft dysfunction and mortality better than C4d 
alone [14, 26]. Haas et al. reported that biopsies positive for C4d (C4d+) and C3d (C3d+) are 
strongly associated with DSA and allograft dysfunction, while cases with episodes that are 
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only positive for C4d are mostly subclinical [19]. Berry et al. published working formulation 
by pathologists to diagnose “pathological AMR (pAMR)” without the requirement of clinical 
dysfunction or positive DSA (Table 1) [27, 28]. CD59 and CD55 (decay-accelerating factors) 
are used in conjunction with C4d and C3d to indicate aborted complement activation. Lengthy 
incubation times and a granular staining pattern render these assays impractical for clinical 
use [26]. The macrophage antigen CD68 allows identification of subtle accumulations of mac-
rophages within vessels, which helps to differentiate intravascular/perivascular macrophages 
from lymphocytes, thereby excluding ACR. Because interstitial macrophages are commonly 
found in allograft myocardium in a variety of settings, including AMR, ACR, and ischemic 
injury, investigators agree that only macrophages within capillaries and small venules are to 
be considered [29]. The term “intravascular macrophage” was replaced by “activated mono-
nuclear cells” because it was clear that without immunostaining with CD68, intravascular T 
lymphocytes and activated endothelial cells could be misinterpreted as macrophages at the 
2012 ISHLT workshop [28]. Endothelial cell markers CD34 and CD31 can be used to ascertain 
the intravascular location of macrophages/mononuclear cells [30]. Immunopathologic features 
of AMR were summarized in Table 2. Using criteria that included prominent endothelial cell 
swelling and/or vasculitis and the vascular deposition of immunoglobulin and complement, it 
was first defined by Hammond and co-workers [9]. The clinic spectrum of AMR ranges from 
latent AMR to silent AMR, to subclinical AMR, and to clinical AMR. Pathologic evidence of 
AMR appears in silent AMR as C4d deposition in capillaries of an otherwise normal myo-
cardium and progresses to subclinical AMR showing myocardial alterations in the setting of 
C4d deposition but the absence of organ dysfunction. The onset of allograft dysfunction is the 
hallmark of clinical AMR [28, 31].
3.1.1. Surveillance and frequency of immunopathologic assessment
Kfoury et al. recommended that immunostaining for C4d be avoided in the first 2 weeks after 
transplant because a number of perioperative issues can confound staining and interpretation 
[32]. Center-specific approaches to the issue of surveillance vary widely, ranging from none 
to every biopsy. The other question is follow-up of positive immunostaining after therapy of 
AMR. The ISHLT pathology group recommended that subsequent biopsies should be studied 
Category Description
pAMR 0: negative for pathological 
AMR
Both histological and immunopathologic studies are negative
pAMR 1 (H+): histopathologic 
AMR alone
Histological findings positive and immunopathologic findings negative
pAMR1 (I+): immunopathologic 
AMR alone
Histological findings negative and immunopathologic findings positive
pAMR 2: pathological AMR Both histological and immunopathologic findings are present
pAMR 3: severe pathological AMR Severe AMR with histopathologic findings of interstitial hemorrhage, capillary 
fragmentation, mixed inflammatory infiltrates, endothelial cell pyknosis and/or 
karyorrhexis, and marked edema
AMR, antibody-mediated rejection; pAMR, pathological AMR (Source: [28]).
Table 1. The 2013 ISHLT working formulation for pathologic diagnosis of cardiac antibody-mediated rejection.
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by immunostaining until a negative result is achieved in 2011. However, investigators reported 
that capillary staining of C3d cleared within 2 weeks to 1 month, while capillary staining of 
C4d cleared within 1–2 months [26].
3.2. Treatment
Investigators have since reported on its incidence, histopathological features, clinical outcome, 
and treatment. However, clinical series are few and sparse, and the incidence of HR and the 
method of choice for its management remain uncertain and may differ among different cen-
ters [33]. All transplantation centers often prefer pulse steroid as an initial therapy in combina-
tion with plasmapheresis. Otherwise, intravenous cyclophosphamide (0.5 to 1 gm/m2, every 
3 weeks for 4–6 months) may be added to treatment regimen according to the clinical experi-
ence and preferences. In case of recurrent AMR exacerbations, cyclophosphamide and IVIg 
(250 mg/kg/day, 4 days, 4–6 months repeated every 3 weeks) followed by plasmapheresis (5–6 
sessions, 10–14 days) have been suggested. After 2002, rituximab (375 mg/m2, once a week, 
four dose infusions) after plasmapheresis is added to treatment regimen [34].
Plasmapheresis is the cornerstone in the treatment of AMR. Exchange method and double-
filtration technique are among the most used plasmapheresis methods. Both techniques are 
nonselective and eliminate immunoglobulins nonspecifically. Immunoadsorption plasma-
pheresis method using adsorbent membrane is more specific to the removal of antibodies; 
however, it is expensive. Each type of plasmapheresis involves risks such as hypovolemia 
and infection [4, 35, 36].
Plasmapheresis has been always reported in combination with other immunosuppressive 
agents; there is always a possibility of AMR recurrence as a monotherapy. In this context, 
other therapies are to be combined in order to prevent recurrence.
Another issue which is also controversial regarding plasmapheresis is about the number of 
sessions of plasmapheresis to be made and at what intervals. General practice is three to five 
Interpretation AMR limitations
IgG/IgM Immunoglobulin binding + Easily dissociated, short half-life, interobserver variability
C3, C1q Complement activation + Short half-life
C3d/C4d Complement activation + Combination more predictive of AMR than C4d alone, long half-life
HLA-DR Endothelial integrity + Staining always present, but “frayed” pattern indicates capillary 
injury
Fibrin Thrombotic environment + Interstitial extravasation suggests more severe AMR episode
CD55, CD59 Complement inhibitor − Long incubation and granular staining pattern, difficult to be 
interpreted
CD31, CD34, 
CD68
Intravascular macrophages + CD68 confirms macrophage lineage of mononuclear cells, CD31 and 
CD34 are endothelial markers which differentiate macrophages from 
endothelial cells and delineate intravascular localization
AMR, antibody-mediated rejection; HLA, human leukocyte antigens (Source: [14]).
Table 2. Immunopathologic features of antibody-mediated rejection.
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sessions every other day. However, Crespo-Leiro et al. [33] reported that they use plasmapher-
esis every day until the recovery of the clinical status. The author who reported this period may 
extend to the nineteenth day. We perform plasmapheresis every other day for three sessions, 
and if there is no clinical improvement, we extend it up to five sessions in our general practice. 
Cytolytic therapy would be useful especially for those who need inotropics or mechanical cir-
culatory support [13, 16]. Cytolytic therapy may indirectly suppress B lymphocyte activation, 
whereas antithymocyte globulin may directly suppress B-cell function [37, 38].
CD20 protein is a molecule present on the surface of B lymphocytes. Rituximab is a chime-
ric monoclonal antibody raised against the CD20 protein. Combination of rituximab with 
plasmapheresis, IVIg, or steroids was found to increase the success of treatment [39, 40]. 
Complement blockade would be an important strategy for prevention and treatment of 
AMR. Agents targeting C5 and C1 esterase have been evaluated in clinical trials. Eculizumab 
binds to complement protein C5 and inhibits complement. It prevents the breakdown of C5 
and formation of MAC. Since eculizumab cannot decrease the levels of donor-specific anti-
gen, antibody-lowering therapy should be added. Although early studies on the effects of 
eculizumab are promising, the use of eculizumab is limited due to the cost and lack of cover-
age by most insurers [41, 42]. Plasma-derived human C1-inhibitor (20UI/kg/twice weekly), 
an inhibitor which targets the classical complement pathway, was successfully administered 
for caAMR prevention in highly sensitized patients [43, 44]. Two C1-INH products that are 
approved for use by the FDA in the treatment of hereditary angioedema have been evaluated 
in small pilot studies for AMR: Berinert® (CSL Behring, Kankakee, IL, USA) and Cinryze® 
(Shire ViroPharma Inc., Lexington, MA, USA) [45, 46, 47]. A potential limitation of available 
therapies for AMR is the lack of direct effect on the major alloantibody-producing plasma 
cell. In recent years, studies regarding bortezomib, a reversible 26S proteasome inhibitor 
used in the treatment of multiple myeloma, have been reported [48, 49]. These studies rather 
relate to the treatment of AMR in kidney transplantation. Woodle et al. reported promising 
results in this regard [49, 50]. This molecule has been used as a rescue therapy in combina-
tion with other immunotherapies for refractory AMR. Everly et al. treated refractory mixed 
AMR and ACR with kidney transplant recipients. They used a single cycle of bortezomib: 
1.3–1.5 mg/m2 × 4 doses over 11 days (days 1, 4, 8, and 11) [51, 52]. Alemtuzumab is a mono-
clonal antibody that binds to CD52 on the surface of B and T lymphocytes. It depletes mature 
lymphocytes without myeloablation [53]. Woodside et al. reported reversal of recurrent 
severe cardiac rejection [54].
A humanized monoclonal antibody against the IL-6R (tocilizumab) has been used in phase I/
phase II studies for the treatment of chronic active AMR unresponsive with high-dose IVIg 
for patients who are difficult to desensitize. Choi et al. reported that AMR patients who had 
failed high-dose IVIg, rituximab, and plasmapheresis received monthly doses of tocilizumab 
for 6 to 18 months and they found to have good outcomes [55, 56].
Antithymocyte globulins (ATG) are antibodies directed at T-cell lymphocyte. This class of 
drugs is used for active treatment of ACR; thus, they are adapted for AMR treatment, but 
there are few data on their effect. Although there have been patients with AMR treated suc-
cessfully with ATG in combination with other drugs, ATG requires more analysis as part of 
a randomized trial [14, 57]. Furthermore, total lymphocyte radiation is used to treat acute 
rejection but is risky due to its reported effects increasing hematologic malignancies [58]. 
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Our opinion is that pAMR should be considered important due to the long-term survival of 
patients. If patient has pAMR, we perform plasmapheresis every other day for three sessions.
There are limited studies about treatment of subclinical AMR. Patients with subclinical AMR 
are not generally treated, because more data regarding the significance of a positive biopsy 
in the absence of symptoms are needed. Wu et al. reported that 5-year actuarial survival rates 
for the subclinical AMR (86%), treated AMR (68%), and control groups (79%) were not signifi-
cantly different; however, patients with subclinical AMR were more likely to develop cardiac 
allograft vasculopathy than the control group and even tended to do worse than patients with 
treated symptomatic AMR [59]. The incidence of CAV or death in the patients with AMR was 
twice that of the control subjects [13].
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